Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients

Journal of Human Virology

Volumn 1, Issue 7, 1998, Pages 451-456

  Fontaine, Elodie ^a   Lambert, Christine ^a   Servais, Jean ^a   Ninove, Danielle ^a   Plesséria, Jean Marc ^a   Staub, Therèse ^b   Arendt, Vic ^a,b   Kirpach, Pierre ^a   Robert, Isabelle ^a   Schneider, François ^a,c   Hemmer, Robert ^a,b   Schmit, Jean Claude ^a,b  

^a Retrovirology Laboratory Luxembourg   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

Author keywords

Dideoxynucleosides; Drug resistance; Treatment naive patients

Indexed keywords

RNA DIRECTED DNA POLYMERASE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MUTATION; NEWBORN; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; VIROLOGY; VIRUS GENE;

ADULT; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INFANT, NEWBORN; LONGITUDINAL STUDIES; MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 0032195765     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129-142.
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997; 11:F101-F105.
3. Mayers DL, Japour AJ, Arduino JM, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother 1994;38: 307-314.
4. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-699.
5. Schmit J-C, Martinez-Picado J, Ruiz L, et al. Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine containing combination therapy. Antiviral Ther 1998;3:81-88.
6. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A 1995;92:2398-2402.
7. Shafer RW, Iversen AKN, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995; 172:70-78.
8. Schmit J-C, Cogniaux J, Hermans P, et al. Multiple drug resistance in nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996;174:962-968.
9. Schmit J-C, VanLaethem K, Ruiz L, et al. Multiple dideoxynucleoside analog resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998;12:2005-2015.
10. Bloor S, Hertogs K, Desmet RL, Pauwels R, Larder BA. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
11. Winters MA, Colley KL, Girard YA, et al. Phenotypic and molecular analysis of HIV-1 isolates possessing 6 bp inserts in the reverse transcriptase gene that confer resistance to nucleoside analogues. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
12. Whitcomb JM, Limoli K, Wrin T, et al. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
13. de Jong JJ, Jurriaans S, Goudsmit J, et al. Insertion of two amino acids in reverse transcriptase (RT) during antiretroviral combination therapy: implications for resistance against nucleotide RT inhibitors. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
14. Yerly S, Kaiser L, Race E, Clavel F, Perrin L. Reverse transcriptase and protease gene analysis at the time of primary HIV-1 infection. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
15. Grant RM, Hecht FM, Petropoulos CJ, et al. Transmission of HIV-1 resistant to multiple transcriptase and protease inhibitors. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
16. Mayers DL, Yerly S, Perrin L, et al. Prevalence and clinical impact of seroconversion with AZT-resistant HIV-1 between 188 and 1994. Presented at the 2nd National Conference on Retroviruses and Related Infections, 1995.
17. Garcia Lerma JG, Weinstock H, Stang H, et al. Identification and characterization of a novel multidrug resistance mutation (Q151L) in drug-naive HIV-1 seroconverters. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
18. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:341-343.
19. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997;41:284-291.
20. Schmit J-C, Ruiz L, Stuyver L, et al. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. J Virol Methods 1998;73:77-82.
21. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
22. Vandamme A-M, Witvrouw M, Pannecouque C, et al. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In: Kinchington D, Schinazi RF, eds. Methods in Molecular Biology: Antiviral Testing. Totowa, NJ: Humana Press, 1998.
23. Najera I, Richman DD, Olivares I. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994;10:1479-1488.
24. Tisdale M, Kemp SD, Parray NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMMD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993;90:5653-5656.
25. Gomez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998;12:1015-1020.
26. Verhelst R, Verhofstede C, VanDerGucht B, VanWanzeele F, Rossau R, Stuyver L. Prevalence of drug-resistance mutations in the HIV-1 reverse transcriptase and protease region in previously untreated patients from Belgium. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
27. Williams I, Kaye S, Williams DI, Bennett J, Tedder RS, Weller IVD. Antiretroviral drug-resistant genotypic mutations in HIV-infected persons at first diagnosis (1988-1997). Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
28. Riva C, Berlusconi A, Violin M, et al. Prevalence of drug-resistant HIV-1 variants of RT region and natural polymorphism in protease coding region of recently infected individuals. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
29. Kozal M, Leahy N, Hanrahan J, Swacck N, Stapelton J. Genotypic analysis of HIV-1 pol genes from drug-naive patients presenting to clinic between 1993-1998 and drug-experienced patients failing antiretroviral combination therapy with reverse transcriptase inhibitors and protease inhibitors. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
30. Dietrich U, Ruppach H, Gehring S, et al. Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconverters. AIDS 1997;11:1532-1533.
31. Van Laethem K, VanVaerenbergh K, Schmit J-C, et al. Selective PCR for the detection of HIV-1 drug resistance mutations in the follow-up of HIV-1-infected patients. Presented at the Third European Conference on AIDS Research, Munich, Germany, 1998.
32. Respess R, Weinstock H, Luo C-C, et al. Evaluation of three diverse genotyping technologies for the analysis of HIV-1 protease and reverse transcriptase and their application in the surveillance for HIV-1 drug resistance mutations in the USA. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
33. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence of multinucleoside drug resistance among European HIV-1-infected patients receiving various combinations of nucleoside analogues. Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-28, 1998.
34. Gÿnthard HF, Wong JK, Ignacio CC. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998;72:2422-2428.
35. U.S. Centers for Disease Control and Prevention. Update: Provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468-447.